LAUNXP BIOMEDICAL CO., LTD.
TTPEX:687614.05
TWD
-0.45
(-3.10%)
ISIN
TW0006876006
Return %
Stock
S&P 500
1Y
-40.59
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Semi-annual Revenue
TWD
•
in mil. unless spec.Semi-annual Earnings Per Share
TWD
•
in mil. unless spec.Semi-annual Dividends Per Share
TWD
•
in mil. unless spec.Company Description
- CEO
- Chiu Hung Chen
- Full Time Employees
- 27
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- B1 Room, No. 51, Section 2 Taichung TX Taiwan 408
- IPO Date
- Jan 18, 2024
- Website
- launxp.com
- Similar Companies
- Business
- LAUNXP Biomedical Co., Ltd (6876.TWO) is a Taiwan-based biotechnology company focused on the research, development, and preclinical advancement of novel cancer therapies targeting hard-to-treat malignancies. The company develops new chemical entities (NCEs), virus-like particles, and nano-formulation anticancer drugs, including LXP5948 for non-small cell lung cancer (NSCLC) and Alzheimer's disease; LXP5268 for triple negative breast cancer; LXP5101 for pancreatic cancer; LXP1788 for gastrointestinal cancer; and virus-like particles for cancer and genetic defect treatments. It also pursues new indications for carcinoma from chronic disease medicines and innovative drug delivery systems. Founded in 2015 and headquartered in Taichung, Taiwan, LAUNXP operates primarily in the pharmaceuticals and biotechnology sector, serving oncology markets with a pipeline in preclinical stages. The company targets patient populations with high unmet needs in Asia and beyond, emphasizing efficient therapies to improve quality of life. In recent developments, LAUNXP entered a development and commercialization agreement valued at approximately $60 million with Apollomics in April 2025 for vebreltinib, a c-Met inhibitor, combined with an EGFR inhibitor to treat NSCLC in Asian territories excluding mainland China, Hong Kong, and Macau; the deal includes $10 million in upfront payments, up to $50 million in milestones, and royalties. Additional partnerships include collaborations with MicroDoctor Biomedical in December 2024 on microneedle technology for cancer treatment and with Darwin in May 2025 to develop a next-generation microcrystal patch for type 2 diabetes and obesity management. These alliances expand LAUNXP's capabilities in drug delivery and combination therapies.